The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 2, Issue 2, 2013, Pages 133-140

  Borges, Isabela T ^a   Shea, Colin D ^a   Ohayon, Joan ^a   Jones, Blake C ^a   Stone, Roger D ^a   Ostuni, John ^a   Shiee, Navid ^a,b   McFarland, Henry ^a   Bielekova, Bibiana ^a   Reich, Daniel S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

Author keywords

Brain atrophy; Brain volume; Daclizumab; Gray matter; Interferon beta; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; DACLIZUMAB; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN MAPPING; BRAIN SIZE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE DURATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84872800724     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2012.10.002     Document Type: Article

References (50)

1. F. Barkhof, P.A. Calabresi, D.H. Miller, and S.C. Reingold Imaging outcomes for neuroprotection and repair in multiple sclerosis trials Nature Reviews Neurology 5 2009 256 266
2. Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Human Brain Mapping 2012;33(9):2062-71
3. K. Bendfeldt, L. Hofstetter, P. Kuster, S. Traud, N. Mueller-Lenke, and Y. Naegelin Longitudinal gray matter changes in multiple sclerosis-differential scanner and overall disease-related effects Human Brain Mapping 33 2012 1225 1245
4. K. Bendfeldt, S. Kloppel, T.E. Nichols, R. Smieskova, P. Kuster, and S. Traud Multivariate pattern classification of gray matter pathology in multiple sclerosis NeuroImage 60 2012 400 408
5. B. Bielekova, M. Catalfamo, S. Reichert-Scrivner, A. Packer, M. Cerna, and T.A. Waldmann Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis Proceedings of the National Academy of Sciences of the United States of America 103 2006 5941 5946
6. B. Bielekova, T. Howard, A.N. Packer, N. Richert, G. Blevins, and J. Ohayon Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis Archives of Neurology 66 2009 483 489
7. B. Bielekova, and R. Martin Development of biomarkers in multiple sclerosis Brain 127 2004 1463 1478
8. B. Bielekova, N. Richert, M.L. Herman, J. Ohayon, T.A. Waldmann, and H. McFarland Intrathecal effects of daclizumab treatment of multiple sclerosis Neurology 77 2011 1877 1886
9. D. Bouskra, C. Brezillon, M. Berard, C. Werts, R. Varona, and I.G. Boneca Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis Nature 456 2008 507 510
10. D.T. Chard, C.M. Griffin, G.J. Parker, R. Kapoor, A.J. Thompson, and D.H. Miller Brain atrophy in clinically early relapsing-remitting multiple sclerosis Brain 125 2002 327 337
11. D.T. Chard, J.S. Jackson, D.H. Miller, and C.A. Wheeler-Kingshott Reducing the impact of White matter lesions on automated measures of brain gray and white matter volumes Journal of Magnetic Resonance Imaging 32 2010 223 228
12. C.E. Coffey, W.E. Wilkinson, I.A. Parashos, S.A. Soady, R.J. Sullivan, and L.J. Patterson Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging Neurology 42 1992 527 536
13. C.M. Dalton, K.A. Miszkiel, P.W. O'Connor, G.T. Plant, G.P. Rice, and D.H. Miller Ventricular enlargement in MS: one-year change at various stages of disease Neurology 66 2006 693 698
14. N. De Stefano, A. Giorgio, M. Battaglini, M. Rovaris, M.P. Sormani, and F. Barkhof Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes Neurology 74 2010 1868 1876
15. N. De Stefano, S. Narayanan, G.S. Francis, R. Arnaoutelis, M.C. Tartaglia, and J.P. Antel Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability Archives of Neurology 58 2001 65 70
16. M. Filippi, M. Bozzali, M. Rovaris, O. Gonen, C. Kesavadas, and A. Ghezzi Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis Brain 126 2003 433 437
17. M. Filippi, M. Rovaris, M. Inglese, F. Barkhof, N. De Stefano, and S. Smith Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial Lancet 364 2004 1489 1496
18. Gelineau-Morel R, Tomassini V, Jenkinson M, Johansen-Berg H, Matthews PM, Palace J The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Human Brain Mapping, 10.1002/hbm.21402, in press.
19. M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R.A. Rudick, and M. Kooijmans Rate of brain atrophy in relapsing MS decreases during treatment with IFN beta-1a Neurology 64 2005 236 240
20. K.M. Hasan, C. Halphen, A. Kamali, F.M. Nelson, J.S. Wolinsky, and P.A. Narayana Caudate nuclei volume, diffusion tensor metrics, and T(2) relaxation in healthy adults and relapsing-remitting multiple sclerosis patients: implications for understanding gray matter degeneration Journal of Magnetic Resonance Imaging 29 2009 70 77
21. K.M. Hasan, I.S. Walimuni, L.A. Kramer, and R.E. Frye Human brain atlas-based volumetry and relaxometry: application to healthy development and natural aging Magnetic Resonance in Medicine 64 2010 1382 1389
22. O.W. Howell, C.A. Reeves, R. Nicholas, D. Carassiti, B. Radotra, and S.M. Gentleman Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis Brain 134 2011 2755 2771
23. W. Jiang, N.R. Chai, D. Maric, and B. Bielekova Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis J Immunol 187 2011 781 790
24. R. Kapoor, J. Furby, T. Hayton, K.J. Smith, D.R. Altmann, and R. Brenner Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial The Lancet Neurology 9 2010 681 688
25. O. Khan, F. Bao, M. Shah, C. Caon, A. Tselis, and R. Bailey Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study Journal of the Neurological Sciences 312 2012 7 12
26. T. Kuhlmann, G. Lingfeld, A. Bitsch, J. Schuchardt, and W. Bruck Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time Brain 125 2002 2202 2212
27. R. Magliozzi, O. Howell, A. Vora, B. Serafini, R. Nicholas, and M. Puopolo Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology Brain 130 2007 1089 1104
28. R. Magliozzi, O.W. Howell, C. Reeves, F. Roncaroli, R. Nicholas, and B. Serafini A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis Annals of Neurology 68 2010 477 493
29. S. Mesaros, M.A. Rocca, E. Pagani, M.P. Sormani, M. Petrolini, and G. Comi Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years American Journal of Neuroradiology 32 2011 1016 1020
30. P.D. Molyneux, L. Kappos, C. Polman, C. Pozzilli, F. Barkhof, and M. Filippi The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European study group on interferon beta-1b in secondary progressive multiple sclerosis Brain 123 11 2000 2256 2263
31. Nakamura K, Rudick R, Lee JC, Foulds P, Fisher E. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis. American Academy of Neurology; Seattle, WA2010
32. M. Neema, A. Arora, B.C. Healy, Z.D. Guss, S.D. Brass, and Y. Duan Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis Journal of Neuroimaging 19 2009 3 8
33. Perry JSA, Han S, Xu QG, Herman ML, Kennedy LB, Csako G, et al. Inhibition of LTi cell development by cd25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Science Translational Medicine. 2012;4(145). 10.1126/scitranslmed.3004140
34. A. Pfefferbaum, D.H. Mathalon, E.V. Sullivan, J.M. Rawles, R.B. Zipursky, and K.O. Lim A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood Archives of Neurology 51 1994 874 887
35. I. Pirko, C.F. Lucchinetti, S. Sriram, and R. Bakshi Gray matter involvement in multiple sclerosis Neurology 68 2007 634 642
36. J.W. Rose, J.B. Burns, J. Bjorklund, J. Klein, H.E. Watt, and N.G. Carlson Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results Neurology 69 2007 785 789
37. J.W. Rose, H.E. Watt, A.T. White, and N.G. Carlson Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody Annals of Neurology 56 2004 864 867
38. R.A. Rudick, E. Fisher, J.C. Lee, J.T. Duda, and J. Simon Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a Multiple Sclerosis Journal 6 2000 365 372
39. S. Schmutz, N. Bosco, S. Chappaz, O. Boyman, H. Acha-Orbea, and R. Ceredig Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells Journal of Immunology 183 2009 2217 2221
40. M. Sdika, and D. Pelletier Nonrigid registration of multiple sclerosis brain images using lesion inpainting for morphometry or lesion mapping Human Brain Mapping 30 2009 1060 1067
41. N. Shiee, P.L. Bazin, A. Ozturk, D.S. Reich, P.A. Calabresi, and D.L. Pham A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions NeuroImage 49 2010 1524 1535
42. N. Shiee, P.L. Bazin, K.M. Zackowski, S.K. Farrell, D.M. Harrison, and S.D. Newsome Revisiting brain atrophy and its relationship to disability in multiple sclerosis PLoS ONE 7 2012 e37049
43. G. Tao, S. Datta, R. He, F. Nelson, J.S. Wolinsky, and P.A. Narayana Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry Journal of the Neurological Sciences 282 2009 39 46
44. B. Turner, X. Lin, G. Calmon, N. Roberts, and L.D. Blumhardt Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years Multiple Sclerosis Journal 9 2003 21 27
45. S.C. Wuest, J.H. Edwan, J.F. Martin, S. Han, J.S. Perry, and C.M. Cartagena A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy Nature Medicine 17 2011 604 609
46. M. Wylezinska, A. Cifelli, P. Jezzard, J. Palace, M. Alecci, and P.M. Matthews Thalamic neurodegeneration in relapsing-remitting multiple sclerosis Neurology 60 2003 1949 1954
47. D. Wynn, M. Kaufman, X. Montalban, T. Vollmer, J. Simon, and J. Elkins Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta Lancet Neurology 9 2010 381 390
48. R. Zivadinov, L. Locatelli, D. Cookfair, B. Srinivasaraghavan, A. Bertolotto, and M. Ukmar Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy Multiple Sclerosis Journal 13 2007 490 501
49. R. Zivadinov, A.T. Reder, M. Filippi, A. Minagar, O. Stuve, and H. Lassmann Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis Neurology 71 2008 136 144
50. R. Zivadinov, J. Sepcic, D. Nasuelli, R. De Masi, L.M. Bragadin, and M.A. Tommasi A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis Journal of Neurology, Neurosurgery, and Psychiatry 70 2001 773 780